European Journal of Surgical Oncology
Volume 33, Issue 4 , Pages 420-423, May 2007

The significance of the site of recurrence to subsequent breast cancer survival

The Breast Unit, William Harvey Hospital, Ashford, Kent TN24 0LZ, UK

Accepted 6 September 2006.

Abstract 

Aim

To investigate differences in the 3-year survival of patients with recurrent breast cancer dependent on recurrence site.

Methods

The study was a review of 294 patients from a breast cancer database, who were treated for operable breast cancer and subsequently developed a recurrence between 1989 and 2003. Patients were divided into four groups according to the site of first recurrence (local, lymph node, bone or visceral). Breast Cancer Specific Survival (BCSS) was compared using Kaplan–Meier life table analysis and the log rank test.

Results

Patient and tumour characteristics were comparable between the four groups. Survival rates between the recurrence site groups were significantly different. Patients in whom first recurrence was local had the best prognosis with a 3-year BCSS of 83% compared to 33% for patients with first node recurrence (p<0.001), 23% for patients with first bone recurrence (p=0.03) and 13% for patients with first visceral recurrence (p=0.004).

Conclusion

Survival of patients with recurrent breast cancer is associated with the site of first recurrence. The prognosis from recurrence is progressively worse with local, regional, bone and visceral metastasis.

Keywords: Recurrent breast cancer, Survival, Recurrence site

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0748-7983(06)00328-3

doi:10.1016/j.ejso.2006.09.005

European Journal of Surgical Oncology
Volume 33, Issue 4 , Pages 420-423, May 2007